ReviewFrontiers in medicine2026
Focus on sex hormone axis disorder: exploring the susceptibility mechanism of dry eye in perimenopausal women.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye (DE) is a disease that affects the ocular surface in multiple aspects. The main feature of this disease is the disruption of tear film balance. If not effectively controlled, DE can cause ocular discomfort, pain and visual impairment. These problems will seriously affect patients' quality of life. Perimenopausal women are at extremely high risk of DE, and their pathogenesis and risk factors have distinct stage specificity. The core view is that the disorder of sex hormones caused by ovarian failure is the initial and core link leading to the imbalance of tear film homeostasis. On this basis, chronic immune inflammatory response, neuroendocrine changes, perimenopausal depression, sleep disorders and the use of specific drugs such as hormone replacement therapy (HRT), as important contributing factors, further amplify the risk of disease in this group. Through a comprehensive analysis of these multi-level and intertwined risk factors, this review emphasizes the need for individualized management strategies for the prevention and treatment of DE in perimenopausal women, so as to provide theoretical basis and new ideas for the standardized clinical diagnosis and treatment of DE in perimenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.